clinical trial · NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Stemline Therapeutics, Inc.·phase3·recruiting·n = 4,220
Breast CancerElacestrantAnastrozoleLetrozoleExemestaneTamoxifen
brief summary
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
started
Sep 27, 2024
primary completion
Aug 1, 2029
completion
Oct 1, 2032
last updated
Apr 24, 2026
official title
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol